{"id":"lv5fu2-or-capectitabine","safety":{"commonSideEffects":[{"rate":"15–25","effect":"Hand-foot skin reaction (palmar-plantar erythrodysesthesia)"},{"rate":"20–40","effect":"Diarrhea"},{"rate":"20–30","effect":"Nausea and vomiting"},{"rate":"10–20","effect":"Mucositis"},{"rate":"10–20","effect":"Myelosuppression (neutropenia, thrombocytopenia)"},{"rate":"20–30","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"LV5FU2 is a regimen combining 5-fluorouracil (5-FU) with leucovorin (folinic acid), which enhances 5-FU's activity by stabilizing its binding to thymidylate synthase. Capecitabine is an oral prodrug of 5-FU that is metabolized preferentially in tumor tissue. Both agents ultimately block nucleotide synthesis and induce apoptosis in rapidly dividing cancer cells.","oneSentence":"LV5FU2 and capecitabine are fluoropyrimidine chemotherapy agents that inhibit thymidylate synthase and get incorporated into DNA/RNA to disrupt cancer cell replication.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:51.139Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Colorectal cancer (metastatic and adjuvant)"},{"name":"Gastric cancer"},{"name":"Breast cancer"}]},"trialDetails":[{"nctId":"NCT02355379","phase":"PHASE3","title":"Randomised Study Evaluating Adjuvant Chemotherapy After Resection of Stage III Colonic Adenocarcinoma in Patients of 70 and Over","status":"RECRUITING","sponsor":"Federation Francophone de Cancerologie Digestive","startDate":"2015-01","conditions":"Colonic Adenocarcinoma","enrollment":774}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":134,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"LV5FU2 or capectitabine","genericName":"LV5FU2 or capectitabine","companyName":"Federation Francophone de Cancerologie Digestive","companyId":"federation-francophone-de-cancerologie-digestive","modality":"Small molecule","firstApprovalDate":"","aiSummary":"LV5FU2 and capecitabine are fluoropyrimidine chemotherapy agents that inhibit thymidylate synthase and get incorporated into DNA/RNA to disrupt cancer cell replication. Used for Colorectal cancer (metastatic and adjuvant), Gastric cancer, Breast cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}